Recombinant activated factor VII (rFVIIa) in refractory haemorrhage for non-haemophiliacs: an eleven-year single-centre experience.

Nurfatin Mohd ShahChong Soon EuSyahirah Mohamed YusoffMohd Zulfakar MazlanKhairul Bariah JohanNizuwan AzmanJo Anne LimSiti Mardhiana MohamadSiti Salmah NoordinZainab Abdul GhaffarMohd Hasyizan HassanMuhammad Azrul ZabidiNur Arzuar Abdul Rahim

Published in: BMC hematology (2018)

rFVIIa significantly improved coagulation parameters and reduced blood product requirements during refractory haemorrhage. Additionally, usage of rFVIIa in trauma and peripartum haemorrhage patients yield better outcomes than other groups of patients. However, the overall mortality rate remained high.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
type diabetes
risk factors
adipose tissue
patient reported outcomes
weight loss
patient reported
cell free